NYSE:SQZ • US78472W1045
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for SQZ BIOTECHNOLOGIES CO (SQZ).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2022-12-02 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2022-12-01 | Chardan Capital | Maintains | Buy |
| 2022-12-01 | B of A Securities | Downgrade | Buy -> Underperform |
| 2022-11-10 | Chardan Capital | Maintains | Buy |
| 2022-10-20 | HC Wainwright & Co. | Initiate | Buy |
| 2022-10-06 | BTIG | Maintains | Buy |
| 2022-05-25 | Chardan Capital | Initiate | Buy |
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 21M 4.43% | 27.098M 29.04% | 21.478M -20.74% | 24.476M 13.96% | 81.407M 232.60% | 133.22M 63.65% | 618.98M 364.63% | 1.595B 157.68% | 2.995B 87.77% | 111.91M -96.26% | 159.48M 42.51% | |
| EBITDA YoY % growth | -49.72M -51.17% | -67.561M -35.88% | -74.321M -10.01% | 116.76M 257.10% | 129.99M 11.33% | 146.75M 12.89% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -51.06M -48.99% | -68.769M -34.68% | -75.825M -10.26% | -74.69M 1.50% | -40.047M 46.38% | -41.006M -2.40% | 223.46M 644.94% | 629.74M 181.81% | 1.536B 143.91% | -17.978M -101.17% | 18.887M 205.06% | |
| Operating Margin | -243.14% | -253.78% | -353.04% | -305.15% | -49.19% | -30.78% | 36.10% | 39.48% | 51.29% | -16.06% | 11.84% | |
| EPS YoY % growth | N/A | -2.50 49.38% | -2.60 -4.00% | -2.09 19.72% | -0.66 68.55% | -0.63 3.85% | 8.74 1,484.80% | 22.71 159.85% | 53.74 136.59% | -0.06 -100.11% | 0.07 216.67% |
All data in USD
| Q2 / 23 | Q3 / 23 | Q4 / 23 | |
|---|---|---|---|
| EPS Q2Q % growth | -0.61 22.31% | -0.76 1.62% | -0.74 -147.45% |
| Revenue Q2Q % growth | 2.273M -29.30% | 2.98M -13.67% | 14.342M 20.09% |
| EBITDA Q2Q % growth | N/A | N/A | N/A |
| EBIT Q2Q % growth | -18.18M 19.21% | -22.675M 1.83% | -21.968M -139.56% |
All data in USD
6 analysts have analysed SQZ and the average price target is 19.38 USD. This implies a price increase of 4355.17% is expected in the next year compared to the current price of 0.435.
SQZ BIOTECHNOLOGIES CO (SQZ) will report earnings on 2023-08-02, after the market close.
The consensus EPS estimate for the next earnings of SQZ BIOTECHNOLOGIES CO (SQZ) is -0.61 USD and the consensus revenue estimate is 2.27M USD.
The number of analysts covering SQZ BIOTECHNOLOGIES CO (SQZ) is 6.